76. 下垂体性ゴナドトロピン分泌亢進症 Pituitary gonadotropin secretion hyperthyroidism Clinical trials / Disease details
臨床試験数 : 28 / 薬物数 : 46 - (DrugBank : 14) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 19
Showing 1 to 8 of 8 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03963752 (ClinicalTrials.gov) | August 15, 2019 | 22/5/2019 | Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western ... | Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious ... | Idiopathic Precocious Puberty | Drug: Ziyinxiehuo Granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate 3.75mg Injection Drug: Ziyinxiehuo Granules Herbs;Drug: Megestrol AcetateTablet;Drug: LeuprorelinAcetate 3.75mg Injec ... | Children's Hospital of Fudan University | NULL | Recruiting | 5 Years | 8 Years | Female | 164 | Phase 4 | China |
2 | NCT02993926 (ClinicalTrials.gov) | June 24, 2017 | 13/12/2016 | A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (C ... | An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprore ... | Central Precocious Puberty | Drug: Enantone;Drug: GnRH agonist | Takeda | NULL | Completed | N/A | N/A | All | 108 | China | |
3 | NCT02427958 (ClinicalTrials.gov) | August 7, 2015 | 23/4/2015 | A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants A Study to Assess the Safety and Efficacy of Leuprorelinin Central Precocious Puberty in Chinese Par ... | An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelinin the Treatment of ... | Central Precocious Puberty | Drug: Leuprorelin | Takeda | NULL | Completed | 1 Year | 9 Years | All | 307 | Phase 4 | China |
4 | NCT03316482 (ClinicalTrials.gov) | June 11, 2015 | 12/10/2017 | Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty LeuprorelinAcetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty ... | A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of LeuprorelinAcetate DPS ... | Central Precocious Puberty | Drug: Leuplin DPS 11.25mg | Jin Soon Hwang | NULL | Completed | 4 Years | 9 Years | All | 58 | Phase 4 | Korea, Republic of |
5 | NCT02920515 (ClinicalTrials.gov) | September 2012 | 16/8/2016 | Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty | Multi-site Study of Comprehensive Treatment for Children Precocious Puberty | Central Precocious Puberty | Drug: Triptorlin or Leuprorelin;Drug: Zhibo dihuang pills;Drug: Dabu ying pills | Ruijin Hospital | Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital;Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital;Shanghai Children's ... | Completed | 2 Years | 14 Years | Female | 740 | Phase 4 | NULL |
6 | EUCTR2014-004494-16-Outside-EU/EEA (EUCTR) | 03/12/2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children ... | A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11. ... | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Centra ... | Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product’ INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELINACETATE Tr ... | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 72 | United States;Puerto Rico | ||||
7 | EUCTR2014-004493-42-Outside-EU/EEA (EUCTR) | 03/12/2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children ... | A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate theEfficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulationsin Children with Central Precocious Puberty A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate theEfficacy and Safety of Leuproli ... | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Centra ... | Trade Name: trade name depends on the source of the product Product Name: Leuprolide acetate depot INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product Product Name: Leuprolideacetate depot INN ... | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 80 | Phase 3 | United States;Puerto Rico | |||
8 | EUCTR2014-004495-36-Outside-EU/EEA (EUCTR) | 28/11/2014 | A study of Lupron Depot Lupron Depot in treatment of central premature puberty | Study of Lupron Depot in the Treatment of Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Centra ... | Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELINACETATE Tr ... | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 55 | United States |